These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15907144)

  • 1. Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.
    Ribichini F; Ferrero V; Rognoni A; Vacca G; Vassanelli C
    Drugs; 2005; 65(8):1073-96. PubMed ID: 15907144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ischemic potential of drugs related to the renin-angiotensin system.
    Ertl G; Hu K
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2003 Sep; 23(9):1141-52. PubMed ID: 14524646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which patients should be on renin-angiotensin system blockers after coronary surgery?
    Alassar A; Bazerbashi S; Easto R; Unsworth-White J
    Interact Cardiovasc Thorac Surg; 2014 Oct; 19(4):667-72. PubMed ID: 24997188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.
    Hammoud RA; Vaccari CS; Nagamia SH; Khan BV
    Vasc Health Risk Manag; 2007; 3(6):937-45. PubMed ID: 18200812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ACE inhibition on myocardial ischaemia.
    Ferrari R
    Eur Heart J; 1998 Sep; 19 Suppl J():J30-5. PubMed ID: 9796838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function.
    Trevelyan J; Needham EW; Morris A; Mattu RK
    Heart; 2005 Aug; 91(8):1053-7. PubMed ID: 16020596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can angiotensin receptor antagonists prevent restenosis after stent placement?
    Peters S
    Am J Cardiovasc Drugs; 2002; 2(3):143-8. PubMed ID: 14727976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.
    Ikeda N; Nishimura S; Kyo S; Komiyama N; Matsumoto K; Inoue T; Suzuki H
    Circ J; 2006 May; 70(5):548-52. PubMed ID: 16636488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis.
    Pitt B
    Am Heart J; 1994 Dec; 128(6 Pt 2):1328-32. PubMed ID: 7977014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention.
    Xiao-Dong Z; Fei-Fei L; Zhan-Peng W; Xin-Xue L; Zhi-Min D
    Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):172-7. PubMed ID: 27185017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
    Fox DJ; Kibiro M; Eichhöfer J; Curzen NP
    Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.